Seante Health, Education, Labor, and Pensions Commitee Hearing on Monkeypox

For The Washington Post

The Washington Post

staff

Only 2 U.S. states report covid increases, CDC says

Covid Surge - Washington, DC

Caucasian woman tired from working overtime, She has eyestrain from looking at the computer screen for a long time, Blue light is harmful to the eyes.

Contributor

Long Covid and Intimacy

Karnataka makes mask mandatory for people aged 60, Bangalore, India - 19 Dec 2023

COVID Cases Spike Across The U.S.

Staff

Transgender Treatment Florida

Long Covid Liza Fisher

INDONESIA-HEALTH-COVID-VACCINATION

Covid and flu vaccinations

Coronavirus Pandemic 2021 California

Seniors made up 63 percent of covid hospitalizations earlier this year

Centers for Disease Control and Prevention Director, Dr. Mandy Cohen, in Atlanta

Shortage Of COVID Vaccines For Kids

Photographer

Biden COVID Tests

Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

Show NLP summaries collection recirc on article pages

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Kyle Finnegan’s rare hiccup helps Phillies to a 4-3 win in 10 innings

Joey Gallo returns, but Nats endure another quiet offensive night

Walter Johnson’s jersey from 1920 showdown with Babe Ruth sold at auction

In photos: The 149th running of the Preakness Stakes

Book Tour: At home with Amor Towles

Gov. Doug Burgum speaks in support of Trump

‘Never Trump?’ ‘Never Biden’ voters might loom larger.

How Jim Jordan tried to connect the dots on Biden’s $8 million book deal

Lawyer preparation suggests Trump won’t testify in New York trial

Would you eat this weird sandwich? Barry Enderwick would. 

She finished chemo then got a medical degree: ‘The dream is real now’

Puppy abandoned with heart-rending note is adopted, named Minerva

The problem with diversity statements — and what to do about them

Russia shows resilience. There is more to do for Ukraine.

Trump promises tax cuts and fewer rules. CEOs shouldn’t fall for it.

Blue Origin to fly again as space tourism struggles to get off the ground

Why this company’s biggest fans turned against it

These ISIS news anchors are AI fakes. Their propaganda is real.

Carolyn Hax: Friends say to break other plans to avoid offending new man

Ask Amy: Should my husband get a say in what I do with my inheritance?

Ask Amy: Can’t a single woman eat alone without interruption?

The world’s coolest hotels want to tell you a story

6 Airbnb red flags to spot before you make a booking mistake

Flying budget airlines might not be as cheap as it seems

The other side of Punta Cana: A crackdown on Haitians

Top White House aide to meet Netanyahu, who is under political pressure

Live updates: Rescuers struggle to find helicopter carrying Iranian president

Biden’s false claim that inflation was 9 percent when he took office

Did Obamacare ‘massively’ increase the cost of health care?

Trump trial live updates: Closing arguments set for next week; Cohen resumes testimony

Health

Well+Being

Opinions

Higher Education

Education

https://www.washingtonpost.com/coronavirus/

Coronavirus pandemic

Healthy living, including food, fitness, longevity and mental health

See more coverage in your recommendations

See alerts for Health and Wellness developments

Health & wellness

Tips on living better delivered every Thursday

Well+Being newsletter

Health alerts

Health & Science alerts

Dado Ruvic

Moderna <a href="https://www.documentcloud.org/documents/22266043-moderna-complaint?responsive=1&title=1" target=_blank>sued Pfizer and its German partner BioNTech</a> on Friday, alleging that the rival firms improperly used its foundational technology in developing their <a href="https://www.washingtonpost.com/coronavirus/" target="_blank" class="contextual_link">coronavirus</a> vaccine. The suit sets up a legal battle between the most prominent companies that helped curb the coronavirus pandemic in the United States by developing highly effective shots in record time.

“We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,” Moderna Chief Legal Officer Shannon Thyme Klinger said in a company news release. <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Sues-Pfizer-and-BioNTech-for-Infringing-Patents-Central-to-Modernas-Innovative-mRNA-Technology-Platform/default.aspx" target="_blank">The company said it filed suits</a> in U.S. District Court in Massachusetts and in Germany, where BioNTech is headquartered.

The prospect of a legal battle between the mRNA vaccine makers points to the high stakes in the competition between Pfizer, a global pharmaceutical giant, and Moderna, a start-up biotechnology company based in Massachusetts that had never sold a product before it won emergency authorization from the Food and Drug Administration for its<b> </b>coronavirus vaccine <a href="https://www.washingtonpost.com/health/2020/12/17/covid-fda-moderna-vaccine-2/" target=_blank>in late 2020</a>.

Moderna halts patent fight over coronavirus vaccine with federal government

Patent lawsuits, common in the biotech industry, typically play out over years and often wind up in federal appeals courts. It could be three to five years before Moderna’s dispute with Pfizer-BioNTech is resolved.

Pfizer said Friday it had not fully reviewed the complaint.

“We are surprised by the litigation given the Pfizer/BioNTech COVID-19 vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer,” the company said in an email. “We remain confident in our intellectual property supporting the Pfizer/BioNTech vaccine and will vigorously defend against the allegations of the lawsuit.”

Moderna and Pfizer have made tens of billions of dollars in coronavirus vaccine sales. But Moderna said it is not seeking an injunction against Pfizer’s sale of its vaccine or its removal from the market, in recognition of the need “to ensure continued access to these lifesaving medicines.”

Rather, the outcome of the dispute could prove to be more relevant for future uses of the mRNA technology. The mRNA platform holds the promise of <a href="https://www.washingtonpost.com/health/2022/06/01/hiv-vaccine-covid-vaccine/" target=_blank>future vaccines </a>against influenza, HIV and other diseases.

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,” Moderna chief executive Stéphane Bancel said in the company’s release.

Moderna has been working on RNA vaccines since its founding in 2010. Pfizer partnered with BioNTech, another pioneer in the technology, at the beginning of the pandemic. Both companies produced vaccines in record time as the coronavirus spread in 2020, infecting hundreds of millions of people and crippling economies; the virus has <a href="https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6" target=_blank>killed 6.4 million people worldwide</a>.

Industry fights over global vaccine patents are just warming up

The two shots work in the same way: They deliver a strand of messenger RNA into human cells that instructs the cells to create the unique spike protein that is a distinctive feature on the surface of every coronavirus particle. The spike protein triggers an immune response in the human body that inoculates against infection.

Moderna’s lawsuit alleges Pfizer-BioNTech appropriated two of Moderna’s inventions.

Moderna contends that Pfizer and BioNTech’s shot “has the same exact mRNA chemical modifications” as Moderna’s, according to its news release. Those modifications to mRNA, which Moderna said were validated in 2015, are designed to avoid an undesirable immune response to the presence of the foreign mRNA in the body.

The second invention at issue was developed in response to Middle East respiratory syndrome (MERS), Moderna said. It described the invention as a patented approach to “encode for the full-length spike protein in a lipid nanoparticle formulation for a coronavirus.”

Crucial elements of the science behind both vaccines was supported by the National Institutes of Health and <a href="https://www.washingtonpost.com/health/2021/10/01/barney-graham-covid-vaccines/" target=_blank>developed by NIH scientists</a>. Moderna last year triggered an intellectual property dispute with the government over elements of its vaccine when <a href="https://www.washingtonpost.com/business/2021/11/09/moderna-nih-patent-vaccine/" target=_blank>it left NIH scientists off</a> a draft patent filing; Moderna subsequently <a href="https://www.washingtonpost.com/nation/2021/12/17/covid-omicron-variant-live-updates/#link-UPRB6FILHVA37KYIMOYWIIK7P4" target=_blank>backed off</a> and said it is in discussions with the government to resolve the disagreement.

In its news release Friday, Moderna said none of the patent rights in its suit against Pfizer and BioNTech relate to intellectual property generated during its collaborations with NIH. It added that it is not seeking financial damage awards for Pfizer sales of vaccine to impoverished foreign countries or in any instance where the U.S. government would be responsible.

Everett McKinley Dirksen Award, awarded to Boston Globe Washington Bureau for 19-part "Broken City" series on congressional gridlock and dysfunction

Society of American Business Editors and Writers, Project Award, shared for coverage of the Medicare prescription benefit law

Edited Globe work recognized for the Merriman Smith Memorial Award (about the Iran nuclear pact) and as finalist for the Gerald Loeb Award (about business activities of retired generals) and finalist for the Goldsmith Prize for investigative reporting (about Massachusetts lawmakers’ pensions)

University of Arizona, BS in Journalism

Christopher Rowland joined The Washington Post business team in 2018 after serving as the Washington bureau chief for the Boston Globe, leading coverage of two presidential elections and overseeing national political enterprise reporting. He previously covered health care for the Globe in Boston.